BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 25225797)

  • 1. The KDM2B- let-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy.
    Karoopongse E; Yeung C; Byon J; Ramakrishnan A; Holman ZJ; Jiang PY; Yu Q; Deeg HJ; Marcondes AM
    PLoS One; 2014; 9(9):e107817. PubMed ID: 25225797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of microRNA let-7b expression by KDM2B promotes cancer progression by targeting EZH2 in ovarian cancer.
    Kuang Y; Xu H; Lu F; Meng J; Yi Y; Yang H; Hou H; Wei H; Su S
    Cancer Sci; 2021 Jan; 112(1):231-242. PubMed ID: 33091189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KDM2B mediates the Wnt/β-catenin pathway through transcriptional activation of PKMYT1 via microRNA-let-7b-5p/EZH2 to affect the development of non-small cell lung cancer.
    Zhang X; Yin Z; Li C; Nie L; Chen K
    Exp Cell Res; 2022 Aug; 417(2):113208. PubMed ID: 35580699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysine-specific demethylase 2B (KDM2B)-let-7-enhancer of zester homolog 2 (EZH2) pathway regulates cell cycle progression and senescence in primary cells.
    Tzatsos A; Paskaleva P; Lymperi S; Contino G; Stoykova S; Chen Z; Wong KK; Bardeesy N
    J Biol Chem; 2011 Sep; 286(38):33061-9. PubMed ID: 21757686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of EZH2 expression in myelodysplastic syndromes.
    Cabrero M; Wei Y; Yang H; Ganan-Gomez I; Bohannan Z; Colla S; Marchesini M; Bravo GM; Takahashi K; Bueso-Ramos C; Garcia-Manero G
    Leuk Res; 2016 May; 44():1-7. PubMed ID: 26970171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KDM2B is involved in the epigenetic regulation of TGF-β-induced epithelial-mesenchymal transition in lung and pancreatic cancer cell lines.
    Wanna-Udom S; Terashima M; Suphakhong K; Ishimura A; Takino T; Suzuki T
    J Biol Chem; 2021; 296():100213. PubMed ID: 33779563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
    Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
    Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome.
    Xu F; Liu L; Chang CK; He Q; Wu LY; Zhang Z; Shi WH; Guo J; Zhu Y; Zhao YS; Gu SC; Fei CM; Li X
    Oncotarget; 2016 Feb; 7(7):8119-30. PubMed ID: 26812882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway.
    Kottakis F; Polytarchou C; Foltopoulou P; Sanidas I; Kampranis SC; Tsichlis PN
    Mol Cell; 2011 Jul; 43(2):285-98. PubMed ID: 21777817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The downregulation of GFI1 by the EZH2-NDY1/KDM2B-JARID2 axis and by human cytomegalovirus (HCMV) associated factors allows the activation of the HCMV major IE promoter and the transition to productive infection.
    Sourvinos G; Morou A; Sanidas I; Codruta I; Ezell SA; Doxaki C; Kampranis SC; Kottakis F; Tsichlis PN
    PLoS Pathog; 2014 May; 10(5):e1004136. PubMed ID: 24830456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.
    Xu F; Li X; Wu L; Zhang Q; Yang R; Yang Y; Zhang Z; He Q; Chang C
    Ann Hematol; 2011 Jun; 90(6):643-53. PubMed ID: 21125401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Epigenetic Factor KDM2B Regulates EMT and Small GTPases in Colon Tumor Cells.
    Zacharopoulou N; Tsapara A; Kallergi G; Schmid E; Alkahtani S; Alarifi S; Tsichlis PN; Kampranis SC; Stournaras C
    Cell Physiol Biochem; 2018; 47(1):368-377. PubMed ID: 29772566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NDY1/KDM2B functions as a master regulator of polycomb complexes and controls self-renewal of breast cancer stem cells.
    Kottakis F; Foltopoulou P; Sanidas I; Keller P; Wronski A; Dake BT; Ezell SA; Shen Z; Naber SP; Hinds PW; McNiel E; Kuperwasser C; Tsichlis PN
    Cancer Res; 2014 Jul; 74(14):3935-46. PubMed ID: 24853546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The epigenetic factor KDM2B regulates cell adhesion, small rho GTPases, actin cytoskeleton and migration in prostate cancer cells.
    Zacharopoulou N; Tsapara A; Kallergi G; Schmid E; Tsichlis PN; Kampranis SC; Stournaras C
    Biochim Biophys Acta Mol Cell Res; 2018 Apr; 1865(4):587-597. PubMed ID: 29408056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome.
    Shirahata-Adachi M; Iriyama C; Tomita A; Suzuki Y; Shimada K; Kiyoi H
    Leuk Res; 2017 Dec; 63():90-97. PubMed ID: 29127861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression.
    Ning X; Shi Z; Liu X; Zhang A; Han L; Jiang K; Kang C; Zhang Q
    Cancer Lett; 2015 Apr; 359(2):198-205. PubMed ID: 25595591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.
    Au SL; Wong CC; Lee JM; Fan DN; Tsang FH; Ng IO; Wong CM
    Hepatology; 2012 Aug; 56(2):622-31. PubMed ID: 22370893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes.
    Gawlitza AL; Speith J; Rinke J; Sajzew R; Müller EK; Schäfer V; Hochhaus A; Ernst T
    J Cancer Res Clin Oncol; 2019 Nov; 145(11):2835-2843. PubMed ID: 31506740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-cancer Effects of Curcumin on Myelodysplastic Syndrome through the Inhibition of Enhancer of Zeste Homolog-2 (EZH2).
    Ma L; Zhang X; Wang Z; Huang L; Meng F; Hu L; Chen Y; Wei J
    Curr Cancer Drug Targets; 2019; 19(9):729-741. PubMed ID: 30747066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation.
    Mu W; Starmer J; Yee D; Magnuson T
    Epigenetics Chromatin; 2018 Dec; 11(1):71. PubMed ID: 30522506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.